查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950438

C1-INH替代疗法市场按产品类型、适应症、给药途径、最终用户和分销管道划分，全球预测，2026-2032年

C1-INH Replacement Therapy Market by Product Type, Indication, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，C1-INH 替代疗法市场价值将达到 14.5 亿美元，到 2026 年将成长至 16.4 亿美元，到 2032 年将达到 35.2 亿美元，复合年增长率为 13.50%。

关键市场统计数据
基准年 2025 14.5亿美元
预计年份：2026年 16.4亿美元
预测年份 2032 35.2亿美元
复合年增长率 (%) 13.50%

影响 C1-INH 替代疗法市场的临床因素、治疗方法和运作实际情况的权威概述

C1-INH替代疗法在罕见疾病医学和精准临床管理领域占据着至关重要的地位，其实证依据基于遗传性和后天性补体路径失调。因C1阻碍要素缺乏而发生血管性水肿的患者面临潜在的危及生命的急性发作，需要定期预防策略和及时干预。该疗法涵盖血浆来源和重组产品，每种产品都体现了不同的生产模式、安全性考虑和给药方法，这些因素都会影响临床应用和治疗路径。

技术创新、不断变化的法规和医疗服务模式正在重新定义 C1-INH 疗法的临床应用、安全预期和推广动态。

受技术进步、法规演变和医疗服务模式变革的推动，C1-INH疗法领域经历了变革性转变。血浆处理技术的进步，包括奈米过滤和检验的病原体减少技术，提高了血浆衍生产品的安全性。同时，重组表达系统的创新提高了生物製药生产的一致性和扩充性，并提供了可降低血浆依赖风险的替代供应模式。

2025年关税调整及其对C1-INH疗法采购、库存计画和持续取得的重组，将对营运和采购产生连锁影响。

2025年的关税和贸易政策变化给美国供应链中的製造商和经销商带来了复杂的阻力以及区域成本压力。关税调整影响了原料和成品生物製药的进口经济效益，尤其是从国际供应商采购的血浆衍生成分和特殊试剂。因此，筹资策略进行了调整，以降低跨境价格波动带来的风险，并维持关键治疗药物的持续供应。

一种深入的、以细分市场主导的观点，揭示了产品类型、临床适应症、给药途径、临床环境和分销管道如何驱动差异化的临床和商业策略。

细分市场分析揭示了在评估产品类型、适应症、给药途径、最终用户和分销管道时，需求驱动因素和临床偏好路径的细微差别。按产品类型划分，市场包括血浆来源的C1-INH和重组C1-INH。血浆来源的产品进一步细分为奈米过滤C1-INH和巴氏杀菌C1-INH，这会影响安全性认知、捐赠者依赖风险以及临床医生在做出处方决策时的舒适度。依适应症划分，产品分为急性治疗和预防性治疗，预防性治疗进一步细分为长期预防性治疗和短期预防性治疗。这些区分决定了临床试验设计、真实世界证据的优先顺序和患者选择标准。

不同地区法规结构、医疗基础设施和支付方环境的差异如何塑造个人化的医疗服务取得、商业化和病患支援路径

区域趋势将对美洲、欧洲、中东和非洲以及亚太地区的医疗服务取得、监管时间表和服务提供结构产生深远影响。在美洲，临床专家中心和先进的专科护理网络依然存在，这有助于推广新型製剂和居家照护模式；同时，监管和报销体系更加重视专科治疗管理中的疗效比较和基于价值的合约模式。

深入分析决定市场影响力和长期商业性永续性的竞争定位、产品差异化和策略发展。

C1-INH市场的竞争主要由传统血浆衍生产品供应商和开发重组平台的生物技术公司共同推动，各方都力求透过安全性声明、先进的给药方案和服务体系来脱颖而出。成熟的血浆衍生产品生产商强调其长期安全性记录、病原体减少技术和丰富的临床经验，因此更受重视成熟风险缓解方案的医院处方集和专科医生的青睐。同时，重组产品开发商则着重强调其扩充性生产、减少对捐赠者依赖和成本稳定性等潜在优势，以吸引寻求供应来源多元化的支付方和采购部门。

製造商和相关人员需要製定明确的策略重点，以增强供应链韧性，加速居家医疗保健的普及，并根据可衡量的患者疗效调整报销机制。

产业领导者必须采取果断行动，应对报销压力、供应链波动和不断变化的临床需求，同时推动以病人为中心的医疗服务。首先，应投资多元化的生产和采购策略，以降低受国际贸易波动的影响，并增强血浆衍生产品和筹资策略产品线的供应连续性。其次，应优先考虑皮下製剂和居家医疗支援工具的研发和监管申报，因为这些产品对患者的生活品质和依从性有显着影响。

采用严谨的混合调查方法，结合临床证据综合、相关人员访谈和供应链分析，以产生可操作的策略洞见。

本研究整合了同行评审的临床文献、监管核准资讯、产品标籤和公司披露信息，并结合对临床医生、支付方代表和供应链专家的初步定性访谈，全面展现了C1-INH治疗领域的现状。调查方法结合了从临床试验资料库和安全性资料库中系统提取证据，以及与专家进行有针对性的咨询，以检验发展趋势并解读其对医疗服务运作的影响。

整合临床、营运和商业性的必要因素将有助于实现C1-INH替代疗法的持续可及性和以患者为中心的推广应用。

C1-INH替代疗法是一个充满活力的治疗领域，临床创新、营运韧性和以患者为中心的护理模式共同决定着该领域的成功。产品类型的不断发展，包括血浆衍生安全製程和重组生产技术的进步，在拓展治疗选择的同时，也带来了药物取得和采购的新考量。同时，皮下製剂和居家医疗模式的转变正在重塑病患体验和临床工作流程，迫使相关人员重新评估培训、报销和支持基础设施。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的 C1-INH 替代疗法市场

  • 血浆来源的C1-INH
    • 奈米过滤C1-INH
    • 巴氏杀菌 C1-INH
  • 重组C1-INH

9. 依适应症分類的 C1-INH 替代疗法市场

  • 急性治疗
  • 预防
    • 长期预防性治疗
    • 短期预防

10. 依给药途径分類的C1-INH替代疗法市场

  • 静脉注射
  • 皮下注射

第十一章 以最终用户分類的C1-INH替代疗法市场

  • 居家医疗环境
  • 医院
  • 专科诊所

12. 按分销管道分類的 C1-INH 替代疗法市场

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 C1-INH替代疗法市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 按组别分類的C1-INH替代疗法市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国 C1-INH 替代疗法市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 美国C1-INH替代疗法市场

第十七章 中国C1-INH替代疗法市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca PLC
  • Biotest AG
  • CSL Behring GmbH
  • GlaxoSmithKline plc
  • Grifols SA
  • Kedrion SpA
  • LFB SA
  • Merck & Co. Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Pharming Group NV
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4F7A6D4FD864

The C1-INH Replacement Therapy Market was valued at USD 1.45 billion in 2025 and is projected to grow to USD 1.64 billion in 2026, with a CAGR of 13.50%, reaching USD 3.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.45 billion
Estimated Year [2026] USD 1.64 billion
Forecast Year [2032] USD 3.52 billion
CAGR (%) 13.50%

An authoritative overview of clinical drivers, therapeutic modalities, and operational realities that define the C1-INH replacement therapy landscape

C1-INH replacement therapy occupies a critical niche at the intersection of rare disease therapeutics and precision clinical management, with an evidence base rooted in hereditary and acquired complement pathway dysregulation. Patients experiencing angioedema driven by C1 inhibitor deficiency face episodic, potentially life-threatening events that demand timely intervention and consistent prophylactic strategies. The therapeutic portfolio spans plasma-derived and engineered recombinant modalities, each reflecting distinct manufacturing paradigms, safety considerations, and delivery approaches that influence clinical adoption and care pathways.

Clinicians, payers, and health systems increasingly prioritize therapies that combine robust clinical efficacy with manageable administration profiles and clear safety margins. As a result, stakeholders evaluate products not only on biochemical potency but also on characteristics such as viral inactivation processes, subcutaneous formulations that support home administration, and stable supply chains that minimize treatment disruptions. Regulatory approvals and guideline endorsements play a pivotal role in shaping treatment algorithms, while patient advocacy and real-world outcome data continue to inform best practices and access strategies.

Together, these dynamics underscore the complexity and urgency surrounding C1-INH replacement therapy decisions. This introduction frames subsequent analysis by highlighting clinical drivers, product differentiation, and the operational realities that market participants must navigate to improve patient outcomes and sustain commercial viability.

How technological innovation, regulatory evolution, and care delivery shifts are redefining clinical use, safety expectations, and adoption dynamics for C1-INH therapies

The C1-INH landscape has undergone transformative shifts driven by technological progress, regulatory evolution, and changes in care delivery. Advances in plasma processing, including nanofiltration and validated pathogen-reduction techniques, have strengthened the safety profile of plasma-derived products. At the same time, innovations in recombinant expression systems have improved the consistency and scalability of biologic manufacturing, offering alternative supply models that can mitigate plasma-dependency risks.

Concurrently, regulatory frameworks have adapted to accommodate novel product attributes and alternative routes of administration. Approval pathways have increasingly recognized subcutaneous formulations as facilitators of home-based care, and guideline updates have integrated emerging evidence on long-term prophylaxis benefits for specific patient cohorts. These regulatory and clinical shifts have catalyzed broader adoption of self-administration practices, reshaping training requirements, patient education, and reimbursement discussions.

Market entry of new formulation types and incremental clinical data have also affected payer assessments and hospital formulary decisions. Value propositions now lean heavily on total-care considerations including reduced emergency interventions, improved quality-of-life metrics, and enhanced adherence potential. In turn, manufacturers focus on lifecycle evidence generation, patient support services, and differentiated supply chain reliability to secure preference among clinicians and care networks.

The cascading operational and procurement consequences of tariff shifts in 2025 and how they reshaped sourcing, inventory planning, and access continuity for C1-INH therapies

Policy changes affecting tariffs and trade in 2025 have created complex headwinds and localized cost pressures for manufacturers and distributors operating within the United States supply chain. Tariff adjustments have influenced the economics of importing raw materials and finished biologic products, particularly where plasma-derived components or specialized reagents are sourced from international suppliers. As a result, procurement strategies have adjusted to reduce exposure to cross-border pricing volatility and to preserve continuity of supply for critical therapies.

Manufacturers responded by revisiting sourcing footprints, increasing nearshoring of certain production activities, and renegotiating supplier contracts to incorporate tariff contingencies. These operational adaptations carry implications for production lead times, warehousing requirements, and inventory policies. Health systems and specialty pharmacies, in turn, evaluated their contracting terms and stocking protocols to anticipate potential cost shifts and to maintain availability for patients dependent on regular dosing regimens.

Importantly, tariff-driven cost pressures have accelerated stakeholder conversations around localized manufacturing investments and strategic partnerships that can insulate supply chains from future trade policy fluctuations. Payers and procurement teams have intensified scrutiny of total cost of care and of contractual levers that can stabilize patient access while preserving therapeutic continuity despite an evolving trade environment.

Deep segmentation-led perspective revealing how product type, clinical indication, administration routes, care settings, and distribution channels drive differentiated clinical and commercial strategies

Segmentation analysis reveals nuanced drivers of demand and routes to clinical preference when evaluated across product type, indication, route of administration, end user, and distribution channel. Based on product type, the market includes Plasma Derived C1-INH and Recombinant C1-INH, with plasma-derived offerings further differentiated by Nanofiltered C1-INH and Pasteurized C1-INH, which influence perceived safety, donor-dependency risks, and clinician comfort during prescribing decisions. Based on indication, products are assessed for Acute Treatment and Prophylaxis, with prophylactic use subdivided into Long Term Prophylaxis and Short Term Prophylaxis; these distinctions determine clinical trial designs, real-world evidence priorities, and patient selection criteria.

Based on route of administration, Intravenous and Subcutaneous options dictate care pathway design and patient education needs, with subcutaneous formulations facilitating homecare adoption and intravenous formulations often remaining hospital- or clinic-centered. Based on end user, care settings span Homecare Setting, Hospital, and Specialty Clinic, each carrying different operational requirements, training protocols, and reimbursement interactions. Based on distribution channel, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy models shape logistics, adherence support, and patient convenience.

By integrating these segmentation lenses, stakeholders can prioritize product development, commercial tactics, and service offerings that align with clinician workflows and patient preferences. For example, a recombinant subcutaneous option targeted at long-term prophylaxis for home-based administration will necessitate distinct training, adherence monitoring, and reimbursement positioning compared with a nanofiltered intravenous product optimized for acute inpatient management. These segmentation-driven insights support focused evidence generation, tailored payer engagement, and differentiated commercialization strategies.

How distinct regulatory frameworks, care infrastructures, and payer environments across major regions create tailored pathways for access, commercialization, and patient support

Regional dynamics profoundly influence access, regulatory timelines, and the structure of service delivery across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas continue to feature concentrated centers of clinical expertise and advanced specialty care networks that facilitate uptake of novel formulations and homecare models, while regulatory and reimbursement ecosystems emphasize comparative effectiveness and value-based contracting to manage specialty therapeutics.

In Europe, Middle East & Africa, variant national regulatory approaches and heterogeneous payer landscapes create diverse access pathways; some markets prioritize therapeutic guidelines and centralized reimbursement, whereas others require localized evidence and negotiation. In these regions, collaboration with regional clinical societies and local patient advocacy groups often accelerates guideline inclusion and formulary consideration. In the Asia-Pacific region, rapid healthcare infrastructure development and growing specialty pharmacy capabilities are increasing opportunities for early adoption, though market entry strategies must account for manufacturing approvals, local clinical practice patterns, and variable reimbursement criteria.

Across all regions, logistical considerations such as cold-chain integrity, plasma sourcing constraints, and distribution channel maturity shape the practicalities of delivering C1-INH therapies. Consequently, manufacturers and distributors tailor go-to-market plans to each region's regulatory cadence, clinical network density, and payer expectations, while investing in localized evidence generation and patient support programs to reduce barriers to access and optimize long-term adherence.

An incisive view of competitive positioning, product differentiation, and strategic maneuvers that determine market influence and long-term commercial resilience

Competitive dynamics in the C1-INH arena are driven by a mix of legacy plasma-derived suppliers and biotechnology companies developing recombinant platforms, each pursuing differentiation through safety assertions, administration advances, and service ecosystems. Established plasma-derived manufacturers emphasize long-term safety records, pathogen-reduction technologies, and extensive clinical experience, which resonate with hospital formularies and specialist prescribers that value proven risk mitigation practices. Conversely, recombinant product developers highlight manufacturing scalability, reduced donor dependency, and potential cost-stability benefits that appeal to payers and procurement teams seeking supply diversification.

Strategic maneuvers among industry participants include targeted clinical programs to support prophylactic indications, investments in subcutaneous delivery mechanisms to enable homecare adoption, and deployment of patient support and training services to improve adherence. Collaboration with specialty pharmacies, integrated delivery networks, and patient advocacy organizations remains central to building trust and facilitating real-world evidence generation. In parallel, portfolio strategies increasingly integrate lifecycle plans such as formulation improvements, pediatric-focused studies, and labeled expansions to secure long-term relevance in clinical pathways.

From a commercial perspective, differentiators extend beyond core product attributes to encompass supply-chain resilience, responsiveness to tariff and trade shifts, and the ability to provide comprehensive value-based contracting tools. These company-level strategies determine influence over prescribing patterns, access negotiations, and long-term positioning in patient-centric care models.

Clear strategic priorities for manufacturers and stakeholders to strengthen supply resilience, accelerate homecare adoption, and align reimbursement with measurable patient outcomes

Industry leaders must act decisively to navigate reimbursement pressures, supply-chain variability, and evolving clinical expectations while advancing patient-centered care. First, invest in diversified manufacturing and sourcing strategies that reduce exposure to international trade fluctuations and strengthen supply continuity for both plasma-derived and recombinant product lines. Second, prioritize development and regulatory submission pathways for subcutaneous formulations and homecare enablement tools, as these elements materially affect patient quality of life and adherence behaviors.

Simultaneously, commit to robust evidence generation that addresses prophylactic subpopulations, comparative safety across nanofiltration and pasteurization methods, and real-world outcomes tied to administration routes and care settings. Engage proactively with payers and hospital decision-makers to design outcomes-based agreements and bundled care models that align reimbursement with demonstrated reductions in acute care utilization. Additionally, expand patient support networks and digital adherence tools to lower barriers to self-administration and to capture longitudinal safety and efficacy data.

Finally, cultivate partnerships with specialty pharmacies, integrated delivery networks, and regional health authorities to accelerate guideline inclusion and streamline patient access. By operationalizing these recommendations, industry leaders can strengthen market differentiation, reduce systemic risks, and enhance the therapeutic experience for patients reliant on C1-INH replacement therapy.

A rigorous mixed-methods research approach combining clinical evidence synthesis, stakeholder interviews, and supply-chain analysis to produce actionable strategic insights

This research synthesized peer-reviewed clinical literature, regulatory approvals, product labels, company disclosures, and primary qualitative interviews with clinicians, payer representatives, and supply-chain specialists to construct a comprehensive view of the C1-INH landscape. The methodology combined systematic evidence abstraction from clinical trial registries and safety databases with targeted expert consultations to validate trends and interpret operational impacts on care delivery.

To ensure balanced insights, the approach triangulated clinical efficacy and safety data with stakeholder perspectives on formulary decision-making, distribution logistics, and patient support needs. Regional policy reviews and trade analyses informed evaluations of manufacturing footprint implications and procurement strategies in an evolving tariff environment. Throughout, methodological rigor emphasized transparency around sources, variant data interpretations, and areas where emerging evidence necessitates ongoing monitoring.

Limitations included variability in national reporting standards and heterogeneity of real-world evidence capture across care settings, which the research team addressed by weighting high-quality randomized data alongside consistent observational datasets and expert consensus. The combined methodology yields pragmatic conclusions designed to guide strategic decisions across product development, market access, and commercial operations.

Synthesis of clinical, operational, and commercial imperatives that together shape durable access and patient-centered adoption of C1-INH replacement therapies

C1-INH replacement therapy represents a dynamic therapeutic area where clinical innovation, operational resilience, and patient-centered delivery converge to define success. The ongoing evolution of product types, including advances in plasma-derived safety processes and recombinant manufacturing, has expanded therapeutic options while introducing new considerations for access and procurement. Meanwhile, shifts toward subcutaneous formulations and homecare delivery models are reshaping patient experiences and clinical workflows, prompting stakeholders to reassess training, reimbursement, and support infrastructures.

Trade policy fluctuations and regional regulatory diversity have underscored the importance of diversified sourcing, nearshoring where feasible, and proactive engagement with payers and health systems to ensure continuity of care. Segmentation insights clarify that strategic choices around product formulation, indication targeting, administration route, care setting, and distribution channel materially affect adoption patterns and service requirements. As the field matures, stakeholders that integrate robust evidence generation with resilient commercial and operational strategies will be best positioned to deliver consistent patient value and sustainable access.

In sum, thoughtful alignment of clinical differentiation, supply-chain robustness, and payer-centered value propositions will determine which programs attain durable traction in clinical practice and payer formularies, ultimately shaping the future standard of care for patients requiring C1-INH replacement therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. C1-INH Replacement Therapy Market, by Product Type

  • 8.1. Plasma Derived C1-INH
    • 8.1.1. Nanofiltered C1-INH
    • 8.1.2. Pasteurized C1-INH
  • 8.2. Recombinant C1-INH

9. C1-INH Replacement Therapy Market, by Indication

  • 9.1. Acute Treatment
  • 9.2. Prophylaxis
    • 9.2.1. Long Term Prophylaxis
    • 9.2.2. Short Term Prophylaxis

10. C1-INH Replacement Therapy Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Subcutaneous

11. C1-INH Replacement Therapy Market, by End User

  • 11.1. Homecare Setting
  • 11.2. Hospital
  • 11.3. Specialty Clinic

12. C1-INH Replacement Therapy Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. C1-INH Replacement Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. C1-INH Replacement Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. C1-INH Replacement Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States C1-INH Replacement Therapy Market

17. China C1-INH Replacement Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca PLC
  • 18.6. Biotest AG
  • 18.7. CSL Behring GmbH
  • 18.8. GlaxoSmithKline plc
  • 18.9. Grifols S.A.
  • 18.10. Kedrion S.p.A.
  • 18.11. LFB S.A.
  • 18.12. Merck & Co. Inc.
  • 18.13. Octapharma AG
  • 18.14. Pfizer Inc.
  • 18.15. Pharming Group N.V.
  • 18.16. Sanofi S.A.
  • 18.17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL C1-INH REPLACEMENT THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 134. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GCC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 158. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 166. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)